Jupiter Research Capital (Asia) Ltd’s MoonLake Immunotherapeutics MLTX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
– Sell
-13,075
Closed -$255K – 939
2026
Q2
$255K Sell
13,075
-11,602
-47% -$210K 0.03% 587
2026
Q1
$460K Buy
24,677
+2,151
+10% +$35.6K 0.05% 421
2025
Q4
$297K Buy
+22,526
New +$266K 0.06% 411

Other funds holding MLTX

Jupiter Research Capital (Asia) Ltd's MLTX Position: Q3 2026 in Review

Jupiter Research Capital (Asia) Ltd sold out of MoonLake Immunotherapeutics (MLTX) in Q3 2026, closing a stake of 13,075 shares — an estimated $255K sold.

Jupiter Research Capital (Asia) Ltd first reported a position in MLTX in Q4 2025 and held it in 3 quarters. The position peaked at $460K in Q1 2026. 149 funds tracked by Wall St. Rank hold MLTX as of Q3 2026.

  • Jupiter Research Capital (Asia) Ltd reported no remaining MoonLake Immunotherapeutics position as of Q3 2026 after selling out during the quarter.
  • Jupiter Research Capital (Asia) Ltd sold 13,075 MoonLake Immunotherapeutics shares in Q3 2026, an estimated $255K.
  • Jupiter Research Capital (Asia) Ltd first reported a position in MoonLake Immunotherapeutics in Q4 2025 and held it in 3 quarters.
  • Jupiter Research Capital (Asia) Ltd's MoonLake Immunotherapeutics position peaked at $460K in Q1 2026.
  • 149 funds tracked by Wall St. Rank held MoonLake Immunotherapeutics as of Q3 2026.

Based on Jupiter Research Capital (Asia) Ltd's 13F filing for Q3 2026, filed 16 Nov 2026.